Menopause Flashcards
List three obstetrical complications that increase the risk of cardiovascular disease in the post-menopausal woman.
Preeclampsia or gestational hypertension Gestational diabetes Placental abruption Preterm delivery IUGR
What are the three main causes of illness and disability for post-menopausal women?
Cardiovascular disease
Cancer
Osteoporosis-associated fractures
What effect does combined HRT have on the following health risks:
Adverse cardiac events Stroke VTE DM Breast cancer
Adverse cardiac events - women who start combined HRT shortly after menopause are at low risk/possibly reduced risk for the first few years, women who start combined HRT > 10 years after menopause are at increased risk
Stroke - increased risk in general, less so in younger women & with lower doses
VTE - increased risk, more so with oral vs transdermal preparations, more so with combined HRT vs estrogen alone
DM - decreased risk
Breast cancer - unclear (HRT may encourage growth of existing tumours but does not cause new tumours to develop)
Describe the concept of the critical window and how it relates to cardiovascular disease & HRT.
Critical window refers to the timing of initiating HRT
HRT may have anti-atherogenic effects for younger women with healthy coronaries
HRT may have pro-thrombotic/plaque-destabilizing effects in older women with established CAD
Is HRT contraindicated in women with a family history of breast cancer? Why or why not?
No - with a single affected family member > 50 years old, risk is barely increased over population baseline and therefore HRT is reasonable. With more or younger affected family members, the risk is so significantly increased that the effect of HRT is negligible.
Which of the following cannot be effectively treated with vaginal estrogen?
A. Urge incontinence B. Stress incontinence C. Vaginal atrophy D. Recurrent UTIs E. A & B
B. Stress incontinence
List three contraindications to estrogen-containing HRT.
Unexplained vaginal bleeding Acute liver dysfunction Estrogen-dependent cancer Coronary heart disease Previous stroke Active thromboembolic disease
List two contraindications to progesterone-containing HRT.
Unexplained vaginal bleeding
Breast cancer
(Caution in women with liver disease)
Your patient is on continuous HRT for bothersome vasomotor symptoms. She has an episode of bleeding and you perform an endometrial biopsy. The pathology comes back as “proliferative endometrium.” How should you manage this? What if the pathology shows “atrophic endometrium?”
Proliferative: Increase progesterone dose
Atrophic: Decrease progesterone dose
If either persists, consider D&C/hysteroscopy
Your patient discontinues her HRT, but finds herself again bothered by vasomotor symptoms. She decides to restart her HRT. After how long would she be considered a new user of HRT (ie. you should revisit the risks associated with HRT in light of her current age)?
6 months
What is the mechanism by which estrogen protects against osteoporosis?
Estrogen decreases maturation of osteoclast precursors & activity of mature osteoclasts, thereby decreasing bone resorption
What is the difference between the T & Z scores for bone mineral density?
T score - number of standard deviations from expected BMD for a person of the same sex at peak bone mass
Z score - number of standard deviations from average BMD for a person of the same age & weight
How is osteoporosis diagnosed in post-menopausal women? What about in pre-menopausal women?
Post-menopause: T score < -2.5
Pre-menopause: Z score < -2 AND fragility fracture
What role do the following tests play in working up osteoporosis:
- PTH
- Creatinine
- TSH
- 25dihydroxy vitamin D
PTH - r/o primary hyperparathyroidism
Creatinine - r/o secondary hyperparathyroidism due to renal failure
TSH - r/o hyperthyroidism
25dihydroxy vitamin D - r/o osteomalacia
List four categories of medications that can be used to prevent & treat osteoporosis.
Supplements (calcium, vitamin D) HRT SERMs Bisphosphonates Denosumab (antibody to RANK ligand, which activates osteoclast maturation & function) Teriparatide (recombinant PTH)